个人简历
现任中山大学中山医学院教授，博士生导师。2004年毕业于北京大学化学与分子工程学院，师从来鲁华教授，获理学学士学位。2005年进入美国常春藤盟校康奈尔大学(Cornell University)化学系就读，师从Richard Cerione教授，2011年获得理学博士学位。2011年至2015年在美国宾夕法尼亚大学医学院(University of Pennsylvania School of Medicine)从事博士后研究工作，师从美国人文与科学院院士M. Celeste Simon教授。
研究领域
1. 揭示果糖-1，6-二磷酸酶对于肾癌肿瘤的双重抑制作用。2. 以神经母细胞瘤为模型，揭示癌基因MYC调控谷氨酰胺代谢和细胞凋亡的分子机制。
近期论文
1) Li B, Qiu B, Lee DS, Walton ZE, Ochocki JD, Mathew LK, Mancuso A, Gade TP, Keith B, Nissim I, & Simon MC. (2014) Fructose-1, 6-bisphosphatase opposes renal carcinoma progression. Nature, 513(7517):251-255. IF: 42.351 2) Li B & Simon MC. (2013) Molecular Pathways: Targeting MYC-induced Metabolic Reprogramming and Oncogenic Stress in Cancer. Clin. Cancer. Res.19(21):5835-5841. IF: 8.193 3) Qing G, Li B (共同一作), Vu A, Skuli N, Walton ZE, Liu X, Mayes PA, Wise DR, Thompson CB, Maris JM, Hogarty MD, & Simon MC. (2012) ATF4 Regulates MYC-mediated Neuroblastoma Cell Death upon Glutamine Deprivation. Cancer Cell, 22(5):631-644. IF: 23.893 4) Li B, Antonyak MA (共同一作), Zhang J, & Cerione RA. (2012) RhoA triggers a specific signaling pathway that generates transforming microvesicles in cancer cells. Oncogene, 31(45):4740-4749. IF: 8.559 5) Antonyak MA, Li B (共同一作), Boroughs LK, Johnson JL, Bryant KL, Holowka DA, & Cerione RA. (2011) Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells. Proc. Natl. Acad. Sci. USA. 108(12):4852-4857. IF: 9.809 6) Liu Z, Li B (共同一作), Li X, Zhang L, & Lai L. (2011) Identification of small-molecule inhibitors against human leukocyte antigen-death receptor 4 (HLA-DR4) through a comprehensive strategy. J. Chem. Inf. Model. 51(2):326-334. IF: 4.068 7) McConoughey SJ, Basso M, Niatsetskaya ZV, Sleiman SF, Smirnova NA, Langley BC, Mahishi L, Cooper AJ, Antonyak MA, Cerione RA, Li B, Starkov A, Chaturvedi RK, Beal MF, Coppola G, Geschwind DH, Ryu H, Xia L, Iismaa SE, Pallos J, Pasternack R, Hils M, Fan J, Raymond LA, Marsh JL, Thompson LM, & Ratan RR. (2010) Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. EMBO Mol. Med. 2(9):349-370. IF: 8.245 8) Li B, Antonyak MA (共同一作), Druso JE, Cheng L, Nikitin AY, & Cerione RA. (2010) EGF potentiated oncogenesis requires a tissue transglutaminase-dependent signaling pathway leading to Src activation. Proc. Natl. Acad. Sci. USA. 107(4):1408-1413. IF: 9.809 9) Antonyak MA, Li B, Regan AD, Feng Q, Dusaban SS, & Cerione RA. (2009) Tissue transglutaminase is an essential participant in the epidermal growth factor-stimulated signaling pathway leading to cancer cell migration and invasion. J. Biol. Chem. 284(27):17914-17925. IF: 4.6 10) Li B, Liu Z, & Zhang L. (2009) Multiple-docking and affinity fingerprint methods for protein classification and inhibitors selection. J. Chem. Inf. Model. 49(7):1725-1733. IF: 4.068 11) Liu Z, Huang C, Fan K, Wei P, Chen H, Liu S, Pei J, Shi L, Li B, Yang K, Liu Y, & Lai L. (2005) Virtual screening of novel noncovalent inhibitors for SARS-CoV 3C-like proteinase. J. Chem. Inf. Model. 45(1):10-17. IF: 4.068 12) Li B, Cerione RA, & Antonyak MA. (2011) Tissue transglutaminase and its role in human cancer progression. Advances in Enzymology and Related Areas of Molecular Biology John Wiley & Sons, Inc. 78:247-293 (出版章节)
